Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPB-003
- Development stage
- Preclinical
- Lead developer
- Hangzhou Polymed Biopharmaceuticals
- Modality
- Small Molecules
01
Overview
HPB-003 is a preclinical-stage, subfamily-selective small-molecule kinase inhibitor being developed by Hangzhou Polymed Biopharmaceuticals for the treatment of autoimmune diseases. The drug is designed to target specific members of the Janus kinase (JAK) / tyrosine kinase (TYK) family, specifically Tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). By exhibiting a unique inhibition profile against these subfamily members, HPB-003 aims to achieve maximum anti-inflammatory and immunomodulatory efficacy while avoiding the hematological side effects typically associated with broader JAK inhibition (such as JAK2 inhibition).
02
Targets
JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on HPB-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPB-003.